MAHOGANYZanubrutinib Plus Anti-CD20 Antibodies for Relapsed/Refractory Follicular or Marginal Zone Lymphoma

This clinical trial is designed to evaluate the effectiveness of two different treatment combinations for individuals with certain types of lymphoma, specifically relapsed or refractory follicular lymphoma and marginal zone lymphoma. The study aims to determine which treatment is more effective at prolonging the time patients live without their disease worsening. One treatment option includes a combination of zanubrutinib and obinutuzumab for follicular lymphoma, while the other involves zanubrutinib and rituximab for marginal zone lymphoma. This research is important because finding more effective treatments can potentially lead to better outcomes for patients who have not responded well to previous therapies. Participants in this study receive the treatments either orally or through injections, depending on the type of drug. The study closely monitors the patients using advanced imaging techniques like PET/CT scans to assess how the disease responds to the treatments. The main measure of success in this trial is progression-free survival, which means the length of time during and after treatment that the patient lives with the disease without it getting worse. By comparing these treatments, the study seeks to identify which combination offers a longer period of disease control, helping to guide future treatment decisions.